

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT

CNNC HIGH ENERGY INITIATING THE CLINICAL TRIAL OF SMART COBALT-60-BASED CONE BEAM FOCUSED STEREOTACTIC THERAPY SYSTEM

This announcement is made on a voluntary basis by China Isotope & Radiation Corporation (the “**Company**”) to keep shareholders and potential investors informed of the latest business developments of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that, recently, CNNC High Energy Equipment (Tianjin) Co., Ltd. (中核高能(天津)裝備有限公司) (“**CNNC High Energy**”), a wholly-owned subsidiary of the Company, has made significant progress in its project under development named “Smart Cobalt-60-based Cone Beam Focused Stereotactic Therapy System” (the “**Gamma Knife**”), which has successfully entered the clinical trial phase.

The product can be used for systemic diagnosis and treatment of patients, and it is equipped with the Gamma Knife equipment of CBCT image guidance system, which will provide “more accurate, faster, stronger and smarter” medical services for clinical patients. CNNC High Energy will make every effort to prepare for the on-site protection during the clinical trial, so as to lay a solid foundation for early passing the clinical trial, obtaining registration certificate and satisfying marketing conditions of the product.

By order of the Board
China Isotope & Radiation Corporation
Wang Suohui
Chairman

Beijing, the PRC, 30 August 2023

As at the date of this announcement, the Board comprises Mr. Wang Suohui, Mr. Xu Hongchao and Mr. Du Jin as executive Directors; Mr. Chen Shoulei, Mr. Ding Jianmin, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Poon Chiu Kwok, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.